Raloxifene

This classification denotes a selective estrogen receptor modulator with the molecular formula C28H27NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YX9162EO3I, chemically known as methanone, (6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)- but more generally known as raloxifene, which bears US NIH Compound Identifier 5035. European Medicines Agency schedules Raloxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10243MIG. The term RALOXIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 40, No. 6, 1986, List 26). World Health Organization schedules raloxifene in its Anatomical Therapeutic Chemical (ATC) Classification. RALOXIFENE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule raloxifene under HS 29349990 and SITC 51579. As of Q4 2014, RALOXIFENE remains US FDA's Preferred Term for this commodity. Raloxifene bears US NLM identifiers UMLS ID C0244404 and NCI Concept Code C1518. SMILES: S1C(C(C2C1CC(O)CC2)C(=O)C1CCC(OCCN2CCCCC2)CC1)C1CCC(O)CC1.